4.2.2 Antipsychotic depot injections |
Can be used for maintenance when compliance is a problem. |
AMBER Flupentixol decanoate |
injection 20mg/ml, 1mL, 2mL |
concentrate injection 100mg/ml, 0.5mL, 1mL |
AMBER Fluphenazine decanoate |
injection 25mg/ml, 0.5ml amp, |
AMBER Haloperidol decanoate injection 100mg/mL |
AMBER Pipotiazine palmitate injection 50mg/ml |
AMBER Zuclopenthixol decanoate injection 200mg/ml, 500mg/ml |
|
Risperdal Consta® |
Risperdal Consta® restricted use – request from doctor must be sent to chief pharmacist and medical director of Lancashire Care |
Trust before authorised to prescribe |
RED Risperidone (Risperdal Consta®) injection |
25mg, 37.5mg. 50mg |
|
Abilify Maintena®, Xeplion® |
Aripiprazole prolonged-release (PR) suspension for injection and Paliperidone palmitate (PR) suspension for injection are |
recommended as treatment options in the maintenance treatment of schizophrenia in adult patients stabilised with oral |
aripiprazole where both of the following criteria are met; |
|
> where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable |
antipsychotic medication and |
> where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting |
Antipsychotic Injections |
|
RED Aripiprazole (Abilify Maintena®) prolonged release suspension for injection, 400mg powder and solvent |
RED *Paliperidone (Xeplion®) prolonged release suspension for injection, 50mg, 75mg,100mg,150mg |
|
Paliperidone palmitate prolonged release suspension for injection (six monthly) |
Paliperidone palmitate 6-monthly injection is recommended as a treatment option for the maintenance treatment of |
schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable |
products: |
> where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable |
antipsychotic medications, and |
> where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting Antipsychotic |
injections |
RED Paliperidone palmitate prolonged release suspension for injection (six monthly) (Byannli) |
|
|
*MHRA Drug Safety Alert - Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery |
Back to Main Chapter All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service |
Email: info.elmmb@nhs.net |
|
Copyright© 2016 East Lancashire Medicines Management Board. |
All rights reserved. Disclaimer/Terms and conditions |
|
|
|
|
|
|
|
|
|
|